# GLP-1 medicines and birth control: the tirzepatide distinction

Tirzepatide can reduce oral hormonal contraceptive effectiveness. Learn what its label says and why this should not be generalized to every GLP-1.

Canonical: https://velri.co/blog/glp1-birth-control-pcos-absorption-cycle-changes
Publisher: Velri (https://velri.co/about)
Published: 2026-06-26
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Tirzepatide can reduce the effectiveness of oral hormonal contraceptives. Its approved prescribing information gives a specific precaution after treatment begins and after each dose increase. This matters whether or not you have PCOS. [1]

It is a product-specific interaction, so the first question is which medicine you are taking.

## Why does tirzepatide affect the pill?

Tirzepatide delays stomach emptying, which can affect absorption of medicines taken by mouth. The label says that delay is largest after the first dose and diminishes over time. [1]

For people using oral hormonal contraception, the label recommends switching to a nonoral method or adding a barrier method for four weeks after starting tirzepatide and for four weeks after each dose increase. [1]

The appropriate method depends on your circumstances and preferences. A clinician or pharmacist can clarify how the labeled precaution applies to the contraception you use.

## Is semaglutide the same?

Semaglutide also affects stomach emptying, but its label reports no clinically significant effect on the pharmacokinetics of the studied oral contraceptive ingredients, ethinyl estradiol and levonorgestrel. It does not give tirzepatide's four-week contraception instruction. [2]

That distinction is why advice about one ingredient should not be transferred to the whole category. The exact product and any other medication issues still need review. [1][2]

## Where does PCOS fit?

PCOS can involve irregular or absent ovulation and changes in menstrual cycles. It can also coexist with insulin resistance or obesity. Those features make both the metabolic and reproductive history relevant to a treatment discussion. [3]

Irregular cycles make contraception and pregnancy plans worth discussing directly, alongside the medication choice. [1][3]

Pregnancy plans also change the conversation. Weight-management treatment with these medicines is not intended for pregnancy; the labels include fetal-risk precautions and product-specific planning instructions. Raise a planned or possible pregnancy promptly with the prescribing clinician. [1][2]

## Sources
[1] DailyMed - ZEPBOUND- tirzepatide injection, solution
ZEPBOUND- tirzepatide injection, solution
ZEPBOUND KWIKPEN- tirzepatide injection, solution (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b
[2] DailyMed - WEGOVY- semaglutide injection, solution
WEGOVY- semaglutide tablet (2026). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
[3] Polycystic Ovary Syndrome (PCOS) | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development (2026). https://www.nichd.nih.gov/health/topics/pcos

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support